Trocar Pharma touts peer-reviewed radiation countermeasure data for YK-4-250

Trocar Pharma highlighted government-funded preclinical research in Scientific Reports showing oral YK-4-250 improved survival and intestinal recovery in mice exposed to lethal radiation. The findings matter because GI-ARS has no FDA-approved treatment, and the compound may move toward FDA Animal Rule development.

Why it matters: - Gastrointestinal acute radiation syndrome can damage the intestinal lining, trigger systemic infection and lead to death. - No FDA-approved therapy is specifically indicated for GI-ARS. - The new findings suggest YK-4-250 could work both before and after radiation exposure, which is important for emergency preparedness. - The study adds independent, peer-reviewed support for a preclinical biodefense program that has relied in part on federal research funding.

What happened: - Trocar Pharma highlighted a peer-reviewed study published in Scientific Reports on Aug. 5, 2026. - The research tested oral YK-4-250, Trocar Pharma’s lead investigational compound for GI-ARS, in controlled mouse studies. - Researchers reported improved 30-day survival after lethal partial-body radiation exposure in both a prophylactic model and a post-exposure mitigation model. - The work was conducted by scientists at the Armed Forces Radiobiology Research Institute, the Uniformed Services University of the Health Sciences, the University of Oklahoma Health Sciences Center, Georgetown University and Oakwood University.

The details: - Survival in the prophylactic model rose to 81% from 56% in vehicle-treated animals. - Survival in the mitigation model rose to 88% when treatment started one day after exposure, compared with 58% in controls. - Treated animals showed more viable intestinal crypts and lower mucosal injury scores by Day 7. - Researchers observed lower 4-hydroxynonenal levels, a marker of radiation-induced lipid damage, by 56% at Day 4 and 66% at Day 7. - The study also found reduced bacterial translocation to the liver and better intestinal barrier integrity. - Irradiated intestinal tissue showed increased expression of ACE2, a protective enzyme in the renin-angiotensin pathway. - Oral doses up to 100 mg/kg were well tolerated in a pilot safety study over 17 days of observation. - The paper, titled “YK-4–250 mitigates gastrointestinal radiation syndrome and promotes overall survival following partial body radiation injury,” appeared in Scientific Reports 16, 23964 (2026), DOI: 10.1038/s41598-026-53734-7. - The study was supported in part by NIAID’s radiation countermeasures program, AFRRI intramural research funds, a Department of Veterans Affairs Merit Award and Georgetown University support. - Oakwood University contributed to the work, including a key experiment conducted by Dr. Stanton Dulan while he was a postdoctoral fellow in Dr. Brown’s laboratory.

Between the lines: - The data suggest YK-4-250 is showing both preventive and rescue potential, a useful profile for radiation countermeasures. - Independent academic and government involvement may strengthen credibility for a preclinical biodefense asset. - The results are still limited to animal models, so the jump to human benefit remains unproven. - Milton L. Brown, MD, PhD, said the preclinical findings are encouraging, but substantial development remains before the compound can be considered for people. - Damian V. Dolland said the independent, government-supported work matters because third-party validation is important at this stage.

What’s next: - Trocar Pharma says it has engaged with the FDA on a potential Animal Rule development path for YK-4-250. - The company plans GLP toxicology studies, an IND submission and a Phase 1 study for safety and pharmacokinetics. - YK-4-250 remains investigational and is not approved by the FDA or any other regulator. - No human clinical data exist yet, and safety and effectiveness in people have not been established.

The bottom line: - YK-4-250 has shown notable preclinical survival and gut-protection signals, but the program still has to clear major regulatory and clinical hurdles before it can affect patient care.